A Phase 1/ Phase 2 Study of TTHX1114(NM141)

This is a prospective, multi-center, randomized, masked, vehicle-controlled, dose-escalation study that will include an observational (no intervention) sub-study. Eligible subjects with moderate to severe corneal endothelial dystrophy (defined as Endothelial Cell Density < 2000 mm^2) in at least one eye will be enrolled and randomized.

Key Inclusion Criteria:

• Fuchs Endothelial Corneal Dystrophy, pseudophakic bullous keratopathy, or endothelial dysfunction/ insufficiency due to surgical intervention diagnosed more than 6 months prior to Study Day 0
• Central endothelial cell count of < 2000 mm^2 in at least one eye as determined by the central reading facility

Key Exclusion Criteria:

• Conditions that would impair examination of the anterior chamber structure
• Documented repeated elevated intra ocular pressure (in either eye)
• Corneal transplant (in either eye)
• Posterior Polymorphous Corneal Dystrophy (PPCD)
• History of uveitis or herpetic keratitis
• Cataract surgery within the past 3 months
• Refractive surgery (in the Study Eye)
• Anterior Chamber IOL placement (in the Study Eye)
• Active extra-ocular inflammation from any non-infectious or infectious cause within the past 6 months
• Expected or planned ocular surgery within the next 3 months
• Use of cytotoxic chemotherapy within the last 1 month
• Treatment with a rho kinase inhibitor within the last 3 months
• Use of cyclosporine ophthalmic emulsion or lifitegrast ophthalmic solution in the last 30 days
• Systemic or ophthalmic corticosteroid use in the 30 days prior to Study Day 0 unless approved by the Medical Monitor
• History of significant allergy, hypersensitivity, or intolerance to any drug compound, food, or other substance
• Unwilling to use birth control